tiprankstipranks
In this article:
Blurbs

Analysts’ Top Healthcare Picks: Allena Pharmaceuticals (ALNA), Unity Biotechnology (UBX)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allena Pharmaceuticals (ALNAResearch Report) and Unity Biotechnology (UBXResearch Report) with bullish sentiments.

Allena Pharmaceuticals (ALNA)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals today and set a price target of $4.00. The company’s shares closed last Tuesday at $0.58.

According to TipRanks.com, Moussatos has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.3% and a 39.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Allena Pharmaceuticals is a Moderate Buy with an average price target of $7.50, an 876.6% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.

See today’s best-performing stocks on TipRanks >>

Unity Biotechnology (UBX)

Wedbush analyst Andreas Argyrides reiterated a Buy rating on Unity Biotechnology today and set a price target of $4.00. The company’s shares closed last Tuesday at $1.86, close to its 52-week low of $1.43.

According to TipRanks.com, Argyrides is a 1-star analyst with an average return of -13.5% and a 0.0% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, Clearside Biomedical, and Graybug Vision.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $5.00 average price target, which is a 179.3% upside from current levels. In a report released yesterday, Roth Capital also upgraded the stock to Buy with a $4.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALNA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed